Chemopreventive Effect of Aerosolized Polyphenon E on Lung Tumorigenesis in A/J Mice  by Yan, Ying et al.
Chemopreventive Effect of Aerosolized Polyphenon E on Lung
Tumorigenesis in A/J Mice1
Ying Yan*, Julie Cook*, Jay McQuillan*, Guifang Zhang y, Cory J. Hitzman y,2, Yian Wang*,
Timothy S. Wiedmann y and Ming You*
*Department of Surgery, The Alvin J. Siteman Cancer Center, Washington University School of Medicine, Campus
Box 8109, 660 South Euclid Avenue, St. Louis, MO 63110, USA; yDepartment of Pharmaceutics, University
of Minnesota, Minneapolis, MN 55455, USA
Abstract
Effective chemoprevention of lung cancer in high-risk
patients through the administration of pharmacologic
or nutritional agents is urgently needed. Aerosol in-
halation can deliver chemopreventive agents directly
to the respiratory tract to inhibit the tumorigenic
process. In this study, polyphenon E (PolyE) and ()-
epigallocatechin-3-gallate (EGCG) were administered
by aerosol delivery to A/J mice beginning 2 weeks after
carcinogen treatment and continuing daily by inhala-
tion throughout the remainder of the study (20 weeks).
PolyE decreased tumor load by f 59%. However,
EGCG, both at the same dose and at a higher dose,
failed to inhibit lung carcinogenesis. These results
indicate that aerosol delivery of PolyE, but not EGCG,
may be a useful chemopreventive protocol in subjects
at high risk for lung cancer.
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Introduction
Lung cancer is the leading cause of cancer deaths in both
men and women in the United States [1]. Despite improve-
ment in therapy, the cure rate for lung cancer remains low.
Chemoprevention offers an important approach to de-
creasing the incidence of lung cancers. Chemopreventive
agents with strong efficacy against lung cancer often cause
systemic toxicities and adverse effects by standard delivery
modalities. Toxicities can often prevent the clinical use of
these agents. Targeting of agents to specific areas within
the body can result in better efficacy and lower toxicity.
Proper inhalation of agents leads to direct deposition into
lung tissues, thereby leading to higher concentrations in the
target site and more favorable distribution in comparison to
other means of administration (intravenous, oral, or intra-
peritoneal). Interestingly, aerosol delivery for the chemo-
therapy of lung cancer in humans has been reported to be
effective and to have no adverse effects [2,3]. Aerosol
therapies in several human trials showed shrinkage of pul-
monary metastases of selected histologic changes from
metastatic renal cell cancer [4]. Furthermore, several experi-
ments in animal models used aerosol delivery of chemo-
preventive agents against lung tumorigenesis [5–10]. For
example, aerosol delivery of budesonide at a low dose inhibited
all stages of progression from hyperplasia to adenocarcinoma
in benzo(a)pyrene [B(a)P]– induced mice lung carcinogenesis
without significant systemic toxicity [6,9,10]. Inhaled beclo-
methasone, at doses starting at 4.8 mg/kg, inhibited lung tumor
formation by up to 60% [10]. These results are particularly
noteworthy because these chemopreventive agents were
given after B(a)P dosing, which is analogous to smokers and
former smokers in humans.
Animal studies have shown that green tea is a potent in-
hibitor of lung tumor development [11–16]. Polyphenon E
(PolyE) is a well-defined pharmaceutical-grade mixture of poly-
phenols that contain at least five different catechins: epi-
catechin, gallocatechin gallate, epigallocatechin, epicatechin
gallate (ECG), and ()-epigallocatechin-3-gallate (EGCG),
with EGCG being the most abundant [17–19]. In this study,
animals were exposed to both PolyE and EGCG with a nose-
only exposure system. Exposure units are based on the design
described by Liao et al. [21]. The aerosol system generated
solid particles with uniform size distribution and consistent
outputs for both PolyE and EGCG. Aerosol delivery of PolyE,
but not EGCG, was found to exhibit significant efficacy against
B(a)P-induced mouse lung tumorigenesis.
Materials and Methods
Reagents and Animals
B(a)P (99% pure) and tricaprylin were purchased from
Sigma Chemical Co. (St. Louis, MO). B(a)P was prepared
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immediately before use in animal bioassays by dissolving in
tricaprylin. The chemopreventive agents PolyE and EGCG
were obtained from Mitsui Norin Co. Ltd. (Shizuoka, Japan).
Female A/J mice at 6 weeks of age were obtained from
Jackson Laboratories (Bar Harbor, ME). The use of animals
was approved by the Washington University’s Institutional
Animal Care and Use Committee.
Animal Studies
Female A/J mice were given a single intraperitoneal dose
of B(a)P (100 mg/kg body weight, prepared just before
injection) in 0.2 ml of tricaprylin. Two weeks after B(a)P
injection, the mice were randomized into fours groups: 1) air
control group (to account for stress factors during mouse
handling procedures in aerosol delivery); 2) vehicle control
group; 3) EGCG group (15 mg/ml in water); and 4) PolyE
group (15 mg/ml in water). Treatments by aerosol deliv-
ery continued for 18 weeks (8 min/day and 5 days/week)
(Figure 1A). The mice were exposed singly to aerosol by
placing their noses onto the cone of the apparatus. The mice
in the air group were placed on aerosol cone for 8 minutes
without aerosol treatment to control for potential stress
factors affecting tumorigenesis. The body weights of the
mice were measured every 3 weeks for the duration of treat-
ments. Mice were sacrificed 20 weeks after exposure to the
carcinogen B(a)P by CO2 asphyxiation. Lungs from each
mouse were fixed in Tellyesniczky’s solution [20] overnight,
followed by 70% EtOH. The fixed lungs were evaluated
under a dissecting microscope to obtain fixed surface tumor
count and individual tumor size. Tumor volume was calcu-
lated based on the following formula: mm3 = V = 4/3pr3 [20].
The total tumor volume in each mouse was calculated by the
sum of all tumors. Tumor load was determined by averaging
the total tumor volume of each mouse in each group.
Aerosol Procedure
EGCG or PolyE was aerosolized in a manner similar to
that described earlier [21]. Briefly, EGCG or PolyE was
dissolved in distilled water and atomized into droplets in-
side a custom-built glass baffle with an air stream flowing at
0.5 l/min, using a 1.7-MHz ultrasonic driver. The resulting
cloud was dried using a reflux dryer [22] and then directed
into the nose-only aerosol exposure chamber, which was
also custom-built.
Dried aerosol mass output was monitored gravimetrically
by collecting aerosol particles with glass microfiber filters
(Whatman QMA Grade, 4.7 cm in diameter; Whatman,
Florham Park, NJ) in a filter cartridge (FP-050; Schleicher
and Schu¨ll, Dassel, Germany) at the exit of a drying column
for a fixed period of time.Massmedian aerodynamic (MMAD)
particle size and geometric standard deviation (GSD) were
determined at the exit of the drying column using a cascade
impactor (Anderson Mark II Eight-Stage Nonviable Impactor;
Graseby-Andersen, Atlanta, GA). Distributions were deter-
mined spectrophotometrically, with MMAD particle size and
GSD being calculated from a linear regression analysis of a
probability plot of cumulative undersize mass versus the
logarithm of the cutoff diameter. The stability of catechins
was verified by independent measures of output using high-
performance liquid chromatography (HPLC).
Figure 1. Protocol and toxicity of aerosolized PolyE and EGCG. (A) Protocol. Two weeks after the intraperitoneal injection of B(a)P, all mice were subjected
to aerosol delivery treatment for 8 min/day, 5 days/week. The treatment continued for 18 weeks. (B) Body weight. Mice in all groups were weighed every 3 weeks.
No signs of systematic toxicities and adverse effects were observed. (C) Light photomicrographs of lung tissues treated with aerosolized PolyE. Photomicrographs
are shown at 100 and 400 magnifications on the upper and lower panels, respectively. Black boxes show regions at 400 magnification. (A1 and A2) Control.
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The mass of inhaled LNP aerosol (Minhaled) was calcu-
lated as follows:
Minhaled ¼ ½CaerosolRMVt
W
ð1Þ
where [C]aerosol is the aerosol concentration of catechins, RMV
is the respiratory minute volume of the mouse (0.025 l/min,
based onGuyton’s formula [x]), t is the length of timeof aerosol
exposure (8 minutes), andW is the mouse weight (0.025 kg).
Percent deposition of aerosol within the lung was estimated
from assayed tissue mass and inhaled mass, using the fol-
lowing equation:
% Deposition ¼ Mtissue
Minhaled
 100 ð2Þ
Following aerosol exposure, the mice were sacrificed by
CO2 asphyxiation. Blood was obtained by cardiac puncture,
collected into plastic centrifuge tubes, and quench frozen in
liquid nitrogen. The lung was severed at the carina and
frozen until assayed.
Tissue/Serum Assay Methods
PolyE concentrations in lung and serum samples were
determined by HPLC. The HPLC system consisted of an LC-
10AD pump, a DGU-14A degasser, an SIL-10A autoinjector
affixed with a sample cooler, a CTO-10A column oven, an
SPD-10A UV–Vis detector, a C-R5A chromatopac integrator,
and an SCL-10A system controller (Shimadzu, Columbia,
MD). The HPLC column was SUPELCOSIL LC-18 (25 cm 
4.6 mm, 5 mm), and the wavelength was 277 nm. Stock
solutions were prepared by dissolving PolyE and EGCG
separately in Vc-EDTA buffer consisting of 20% ascorbic acid
and 0.1% EDTA sodium salt in 0.4 M NaH2PO4 buffer at
pH 3.6. The mobile phase consisted of 0.1% H3PO4:EtOAc:
acetylnitrile (97:2:1). The sample chamber temperature and
column temperature were controlled as constants at 4jC
and 35jC, respectively. The flow rate of the mobile phase
for the first 10 minutes was 1 ml/min, and then 1.5 ml/min from
10 minutes until the end. The peak of EGCG was identified
and used to calculate the concentration of PolyE.
Lung tissues were weighed and homogenized in 0.5 ml of
ice-cooled Vc-EDTA buffer, and 0.2 ml of homogenate
aliquots was transferred into centrifuge tubes containing
10 ml of caffeine (1 mg/ml), followed by vortexing for 30 sec-
onds. A 0.2-ml H2O aliquot, 2 ml of methanol, and 2 ml of
acetonitrile were added to the homogenate. Then the sample
was vortexed for 2 minutes and centrifuged at 13,000 rpm
for 15 minutes at 4jC. Supernatants were transferred and
dried under nitrogen gas stream. Residues were recon-
stituted in 0.5 ml of H2O and centrifuged, and 40 ml of the
supernatants was injected into HPLC at 4jC.
An aliquot of 100 ml of each serum sample was trans-
ferred into a centrifuge tube containing 20 ml of Vc-EDTA
buffer and 10 ml of caffeine (1 mg/ml). After vortexing for
30 seconds, the serum was extracted as above for lung
tissue homogenate, except that the residues were reconsti-
tuted in 0.2 ml of H2O.
Statistical Analysis
Tumor multiplicity and tumor load were analyzed by two-
sided Student’s t test using Microsoft Excel 2002 SP-3
(Microsoft, Redmond, WA) to determine differences in the
number and in the size of lung tumors per mouse between
groups. In all t-tests, the level of statistical significance was
set at P < .05.
Results and Discussions
The results of output measurements and aerosol deposition
studies are given in Table 1. Inhaled dose represents the
total mass that is expected to enter the respiratory tract
of mice with a normal breathing pattern, consistent with
Guyton’s formula for respiratory minute volume. Values de-
pend on aerosol production output, airflow rate, and through-
put efficiency in transporting particles to the point of
inhalation. Two different inhaled doses of EGCG and PolyE
were used. The use of an ultrasonic atomizer provides for a
dense aerosol cloud, which largely depends on the proper-
ties of the solvent. Thus, no major differences were seen
between EGCG and PolyE when solution concentrations
were the same. Minor differences may be a result of slight
differences in solution viscosity.
Also given in Table 1 are particle size distributions. As can
be seen, lower concentrations yielded smaller particles (0.7
and 0.9 mm, in comparison to 1.1 and 1.3 mm), consistent
with the fact that the initial drop contained a larger mass
and, with drying, would result in a larger dried particle. All
things being equal, the diameter should increase with the
cube root of the initial mass concentration, which is consis-
tent with the data. GSD is reasonable for ultrasonic atomi-
zation and reflects a fairly narrow distribution in production
that likely is broadened due to the aggregation of particles in
transit. It appears that PolyE yielded somewhat larger mean
sizes, which may be due to differences in particle density.
The deposited mass is given in Table 1, which was
calculated from the assayed lung concentration of EGCG.
For the two doses of EGCG, deposited masses versus body
weight were 277 and 417 mg/kg, corresponding to lung con-
centrations of about 60 and 75 mg/g. In contrast, values for
PolyE were higher at 417 and 664 mg/kg. The mass depos-
ited by PolyE consists of about 60% EGCG and 40% other
catechins. Consistent with deposited masses and reflecting
similar outputs of aerosol device, percent depositions were
about 2% and 1.5% for low and high doses of EGCG, and
2.5% and 2.3% for low and high doses of PolyE, respectively.
Table 1. Doses and Particle Size Distributions of Aerosolized PolyE and
EGCG.
Aerosol Inhaled
Dose
(mg/kg)
MMAD
Particle
Size (mm)
GSD Deposited
Mass
(mg/kg)
Deposition
(%)
EGCG, 7.5 13.4 ± 4.0 0.72 2.1 277 ± 59 2.0
EGCG, 15 28.0 ± 7.4 1.09 1.8 416 ± 64 1.5
PolyE, 7.5 16.6 ± 0.9 0.92 1.8 417 ± 64 2.5
PolyE, 15 29.5 ± 4.8 1.28 1.7 664 ± 82 2.3
Values represent mean ± SD (n z 3).
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For each compound, a lower percent deposition is consistent
with a larger mean particle size; however, a higher deposition
was expected for EGCG due to its smaller mean particle
size. The concentration of EGCG in the serum was much
lower because these animals were sacrificed immediately
after exposure, which does not allow for significant trans-
port of EGCG from the lung to the serum. Values ranged from
0.5 mg/ml to a little over 3 mg/ml (less than 1/20 of lung
concentrations), reflecting the efficiency of aerosol delivery
to the lung.
We did not observe systematic toxicities and other ad-
verse effects within the duration of the bioassays. Two weeks
after the injection of B(a)P, the mice were treated by aerosol
delivery for 18 weeks. During the experiment, all mice
showed great tolerance to treatment with either PolyE or
EGCG. No significant difference in body weights or clinical
evidence of toxicity was observed (Figure 1B). The aerosol
delivery of PolyE and EGCG did not induce noticeable
damage to lung tissues (Figure 1C).
We found that aerosol delivery of PolyE significantly
inhibited lung tumorigenesis. EGCG and PolyE (both at the
dose of 15 mg/ml in solvent) were used to determine their
inhibitory effects on B(a)P-induced lung tumorigenesis. A
detailed histopathological examination was conducted to
determine the degree of lung tumor progression related to
the effect of EGCG and PolyE on tumor development. All
lung nodules were diagnosed as lung adenomas (Figure 2A).
In the PolyE-treated group, the mice showed a significant
decrease in tumor load as 0.9 ± 0.18 mm3 compared to
the air and vehicle control groups (2.17 ± 0.55 and 1.78 ±
0.37 mm3, respectively; Figure 2B). Thus, PolyE treatment
decreased tumor load by 59% compared with the air control
group (P < .05). EGCG treatment did not exhibit signifi-
cant efficacy. The tumor load in the EGCG group was 1.78
± 0.28 mm3, similar to those of the vehicle control group and
the air group (Figure 2B). As expected in postinitiation
protocol, aerosol treatment was initiated 2 weeks after
the injection of B(a)P; both EGCG and PolyE groups (6.7 ±
0.7 and 5.91 ± 0.94 tumors/mouse) had tumor multiplicities
similar to those of air (6.09 ± 0.64) and vehicle (6.55 ± 0.95)
control groups.
Previous studies have shown that aerosol delivery has
the potential advantage of achieving high concentrations of
a test agent at the target site with minimum systemic dis-
tribution [9]. We have shown here that aerosol delivery of
PolyE can be a useful alternative approach for the chemo-
prevention of lung cancer. Thus, aerosol delivery of PolyE
should be considered for further studies in other animal
models of lung cancer and in clinical trials.
Green tea has been shown to be chemopreventive in
several animal models [11–13,23,24]. However, the effect of
the aerosol administration of PolyE and EGCG on lung
tumorigenesis has not been determined. In this study, the
aerosol delivery of PolyE inhibited tumor load, which is
commonly interpreted as tumor growth during tumor pro-
gression. With a concentration of 15 mg/ml in water, PolyE
decreased tumor load by 59% compared with the control
group (Figure 2B). At the same concentration, EGCG did not
show any significant effect on tumor load. This was observed
despite the fact that EGCG is the main component (about
60%) of PolyE [17–19]. These results indicate that for the
chemopreventive efficacy of PolyE from aerosol delivery,
EGCGmay not be the major contributor for PolyE’s inhibitory
effect on mouse lung tumorigenesis when given by aerosol
delivery. Other components of PolyE, such as epicatechin,
gallocatechin gallate, epigallocatechin, and ECG, should be
evaluated in the future [14,25,26]. Alternatively, metabolites
of EGCG or other catechins, which would not be available to
the lung following aerosol administration, may be involved.
Furthermore, it is possible that EGCG could still be the ac-
tive compound, but for its antitumor activity, it may require
another component that is present in PolyE formulation and,
as such, none of the other components in the PolyE may be
biologically active without EGCG or vice versa. Regardless
of the nature of the active agent in PolyE, aerosol delivery of
PolyE can increase its efficacy by achieving high concen-
trations of the agent in lung tissues. Tea polyphenols have
Figure 2. Efficacy of aerosolized PolyE against B(a)P-induced mouse lung
tumorigenesis. (A) Lung adenomas. Light photomicrographs of representa-
tive adenomas from the control group (A1 and A3) and the PolyE group (A2
and A4) at 100 and 400 magnifications, respectively. (B) Effect of PolyE
on tumor load. Aerosol delivery of PolyE 2 weeks after B(a)P initiation
reduced lung tumor load by 59%. Error bars indicate standard error. *P < .05.
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various biologic activities, including antioxidation, modulation
of enzyme systems for metabolizing chemical carcinogens,
inhibition of nitrosylation reactions, scavenging of activated
metabolites of chemical carcinogens, inhibition of tumor
promotion, and induction of apoptosis [15,26,27]. It is likely
that some degree of apoptosis and inhibition of cell pro-
liferation may contribute to decreases in tumor load.
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